Condition: RCC, Renal Cell Cancer · Sponsor: Xijing Hospital
This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET/CT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET/CT in renal cell carcinoma.
This description comes directly from the study's public registry record.
Ying Guo · 0086+15991459177 · guoying01192022@163.com
he rui Li · 0086+17563734669 · 3099595564@qq.com
Always discuss trial participation with your own doctor first.
| Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China | Xi'an, China, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06769893